Gilead Sciences (XSGO:GILD) ROCE % : 21.53% (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Gilead Sciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Gilead Sciences's annualized ROCE % for the quarter that ended in Dec. 2024 was 21.53%.

Gilead Sciences ROCE % Historical Data

The historical data trend for Gilead Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences ROCE % Chart

Gilead Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

4.87

16.37

12.47

15.18

3.41

Gilead Sciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															15.05	-35.97	21.28	11.16	21.53

Gilead Sciences ROCE % Calculation

Gilead Sciences's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	1667	/	( ( (62125 - 11280)	+	(58995 - 12004) )	/ 2 )
	=	1667	/	( (50845	+	46991)	/ 2 )
	=	1667	/	48918
	=	3.41 %

Gilead Sciences's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	9664	/	( ( (54525 - 11724)	+	(58995 - 12004) )	/ 2 )
	=	9664	/	( ( 42801	+	46991 )	/ 2 )
	=	9664	/	44896
	=	21.53 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Gilead Sciences (XSGO:GILD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Gilead Sciences ROCE % Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (XSGO:GILD) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Peru GILD:Mexico 1GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster City, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).